David C Hess

Medicine & Life Sciences

1. Stroke 100%
2. Minocycline 29%
3. Cell- and Tissue-Based Therapy 21%
4. Stem Cells 16%
5. Tissue Plasminogen Activator 15%
6. Neuroprotection 15%
7. Brain 15%
8. Therapeutics 14%
9. Middle Cerebral Artery Infarction 13%
10. Clinical Trials 10%
11. Transplantation 9%
12. Cannabidiol 8%
13. Endothelial Cells 8%
14. Cerebral Hemorrhage 8%
15. Wounds and Injuries 8%
16. Bone Marrow Cells 8%
17. Telemedicine 8%
18. Carotid Stenosis 8%
19. Cerebrovascular Circulation 7%
20. Intercellular Adhesion Molecule-1 7%
21. Traumatic Brain Injury 7%
22. Cerebral Infarction 7%
23. Brain Injuries 7%
24. Hydroxymethylglutaryl-CoA Reductase Inhibitors 6%
25. Brain Ischemia 6%
26. Antiphospholipid Antibodies 6%
27. Cognitive Dysfunction 6%
28. Infarction 6%
29. Cell Transplantation 6%
30. Coronavirus 6%
31. Ischemic Postconditioning 6%
32. Animals 6%
33. Blood Vessels 5%
34. Transplants 5%
35. Reperfusion 5%
36. Up-Regulation 5%
37. Multiple Sclerosis 5%
38. Bone Marrow 5%
39. Neural Stem Cells 5%
40. Ischemia 5%
41. White Matter 5%
42. Drug Repositioning 5%
43. Dystonia 5%
44. Safety 5%
45. Rural Hospitals 5%
46. Nervous System 5%